- Home
- GDV vs CNTA Comparison
GDV vs CNTA Comparison
Compare GDV & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GDV | CNTA |
|---|---|---|
| Founded | 2003 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 3.7B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | GDV | CNTA |
|---|---|---|
| Price | $27.81 | $24.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $37.70 |
| AVG Volume (30 Days) | 186.0K | ★ 1.2M |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | ★ 5.81% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $15,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 118.88 |
| 52 Week Low | $18.04 | $9.60 |
| 52 Week High | $23.00 | $30.58 |
Technical Indicators
Market Signals| Indicator | GDV | CNTA |
|---|---|---|
| Relative Strength Index (RSI) | 62.90 | 39.83 |
| Support Level | $27.06 | $24.17 |
| Resistance Level | $27.93 | $26.01 |
| Average True Range (ATR) | 0.23 | 1.17 |
| MACD | 0.05 | -0.31 |
| Stochastic Oscillator | 88.69 | 11.28 |
Price Performance
Historical ComparisonAbout GDV Gabelli Dividend & Income Trust of Beneficial Interest
Gabelli Dividend & Income Trust operates as a diversified closed-end management investment company. The fund's investment objective is to provide a high level of total return on its assets with an emphasis on dividends and income. To achieve its objective, the fund may invest its assets in dividend-paying securities or other income-producing securities. The fund invests in various sectors, in which Financial Services, Food and Beverage, Health Care, Consumer Products, Electronics, and Computer Software & Services and others.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.